medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2017, Number 2

<< Back Next >>

Ann Hepatol 2017; 16 (2)

A New Paradigm in Gallstones Diseases and Marked Elevation of Transaminases: An Observational Study

Campos S, Silva N, Carvalho A

Language: English
References: 20
Page: 285-290
PDF size: 136.30 Kb.


ABSTRACT

Background. In clinical practice, it is assumed that a severe rise in transaminases is caused by ischemic, viral or toxic hepatitis. Nevertheless, cases of biliary obstruction have increasingly been associated with significant hypertransaminemia. With this study, we sought to determine the true etiology of marked rise in transaminases levels, in the context of an emergency department. Material and methods. We retrospectively identified all patients admitted to the emergency unit at Centro Hospitalar e Universitário de Coimbra between 1st January 2010 and 31st December 2010, displaying an increase of at least one of the transaminases by more than 15 times. All patient records were analyzed in order to determine the cause of hypertransaminemia. Results. We analyzed 273 patients – 146 males, mean age 65.1 ± 19.4 years. The most frequently etiology found for marked hypertransaminemia was pancreaticobiliary acute disease (n = 142;39.4%), mostly lithiasic (n = 113;79.6%), followed by malignancy (n = 74;20.6%), ischemic hepatitis (n = 61;17.0%), acute primary hepatocellular disease (n = 50;13.9%) and muscle damage (n = 23;6.4%). We were not able to determine a diagnosis for 10 cases. There were 27 cases of recurrence in the lithiasic pancreaticobiliary pathology group. Recurrence was more frequent in the group of patients who had not been submitted to early cholecystectomy after the first episode of biliary obstruction (p = 0.014). The etiology of hypertransaminemia varied according to age, cholestasis and glutamic-pyruvic transaminase values. Conclusion. Pancreaticobiliary lithiasis is the main cause of marked hypertransaminemia. Hence, it must be considered when dealing with such situations. Not performing cholecystectomy early on, after the first episode of biliary obstruction, may lead to recurrence.


REFERENCES

  1. Marinho RT. Burden De Hepatologia - Como Vai O Fígado Dos Portugueses. In: Associação Portuguesa de Estudos do Fígado. 2008. http://apef.com.pt/. Accessed September 2012.

  2. Collier J, Bassendine M. How to respond to abnormal liver function tests. Clin Med 2002; 2: 406-9.

  3. Haslett C, Chilvers ER, Boon NA. Davidson’s principles and practice of medicine. 19th Ed. Edinburgh, Churchill Livingstone: 2002.

  4. Kew MC. Serum aminotransferases concentration as evidence of hepatocellular damage. Lancet 2000; 355: 591-2.

  5. Green RM, Flamm S. American Gastroenterological Association Technical Review On The Evaluation Of Liver Chemistry Tests. Gastroenterology 2002; 123: 1367-84.

  6. Ellis G, Goldberg DM, Spooner RJ. Serum Enzyme Tests In Diseases Of The Liver And Biliary Tree. Am J Clin Pathol 1978; 70: 248-58.

  7. Whitehead MW, Hawkes ND, Hainsworth I. A prospective study of the causes of notably raised aspartate aminotransferase of liver origin. Gut 1999; 45: 129-33.

  8. Hall P, Cash J. What is the real function of the liver function tests? Ulster Med J 2012; 81(1): 30-6.

  9. Hayat JO, Loew CJ, Asrress KN. Contrasting liver function test patterns in obstructive jaundice due to biliary structures and stones. Q J Med 2005; 98: 35-40.

  10. De Ritis F, Giuti G, Piccinico F. Biochemical laboratory tests in viral hepatitis and other hepatic diseases. Bull WHO 1965; 32: 59-72.

  11. Adams JT, Clermont GH, Schwartz SI. Serum glutamicoxaloacetic aminotransferases activity in cholecystitis. Surgery 1970; 68: 492-7.

  12. Mayer AD, McMahon MJ. Biochemical identification of patients with gallstones associated with acute pancreatitis on the day of admission to hospital. Ann Surgery 1985; 201: 68-75.

  13. Aragon G, Younossi ZM. When And How To Evaluate Mildly Elevated Liver Enzymes In Apparently Healthy Patients. Clev Clin J Med 2010; 77: 195-204.

  14. European Association for the Study of the Liver. EASL Clinical Practical Guidelines: Management Of Alcoholic Liver Disease. J Hepatol 2012; 57: 399-420.

  15. Fuhrmann V, Jager B, Zubkova A. Hypoxic hepatitis – epidemiology, pathophysiology and clinical management. Wien Klin Wochenschr 2010; 122(5-6): 129-39.

  16. Craxi A, Almasio P. Diagnostic approach to liver enzyme elevation. J Hepatol 1996; 25 Suppl 1: 47-51.

  17. Rodriguez C, Martin L. Estudio diagnóstico del paciente con elevación de las aminotransferases. GH Continuada 2002; 1: 345-8.

  18. Isogai M, Hachisuka K, Yamaguchi A. Etiology and pathogenesis of marked elevation of serum aminotransferases in patients with acute gallstone disease. HPB Surgery 1991; 5: 95-107.

  19. Shaffer EA. Epidemiology and risk factors for gallstone disease: has the paradigm changed in the 21st Century? Best Practice And Research Clinical Gastroenterology 2006; 20: 981-96.

  20. Wasley A. Surveillance For Acute Viral Hepatitis. Morbidity and mortality weekly report. Surveillance Summaries 2008; 57: 1-24.




2020     |     www.medigraphic.com